# Ascendis Pharma A/S (ASND) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $250.17, market value $16.5 billion.

## Valuation
- **P/E (trailing): 19.2×**. Ascendis Pharma A/S trades at 19.2× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 25.0×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.59**. A PEG of 0.59 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 14.1×**. Each dollar of revenue is priced at 14.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 10.2×**. The shares trade at 10.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 62.9×**. Enterprise value is 62.9× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.3%** (5-yr avg -6.7%). Free cash flow equals 2.3% of the market value, above its five-year average of -6.7%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 5.2%**. The inverse of the P/E: 5.2% of the price is earned each year.

## Profitability
- **Gross margin: 91.3%**. Ascendis Pharma A/S keeps 91.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 25.1%**. 25.1% of revenue is left after running the business, an exceptional level.
- **Net margin: -31.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: 140.1%**. A 140.1% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 734.2%**. Return on all capital, debt included, is 734.2%: comfortably above what that capital costs.
- **Return on assets: 56.9%**. Each dollar of assets produces 56.9% of profit.

## Growth
- **Revenue growth (1 yr): 98.0%** (3-yr 141.4%/yr, 5-yr 153.0%/yr). Revenue grew 98.0% over the last year, against 153.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 42.4%**. Earnings per share rose 42.4%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 0.8×**. It would take 0.8 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 2.2×**. Operating profit covers interest 2.2×, thin but manageable.
- **Current ratio: 1.04** (quick 1.04). Current assets cover the next year's liabilities 1.04 times.
- **Altman Z-score: 6.81**. A Z-score of 6.81 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Ascendis Pharma A/S does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (22 analysts). 22 analysts cover Ascendis Pharma A/S; the consensus is strong_buy, with an average price target of $303.89 (+21% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 23.5%** (YTD 16.8%, 3-mo 2.3%). The shares are up 23.5% over twelve months including dividends.
- **From 52-week high: -11.3%** (33.0% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 0.29** (volatility 39%). Beta of 0.29 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ASND · Page: https://foliofundamentals.com/stocks/asnd

Not investment advice.